You have to wait for the inflammation conferences next year to see what might be really positive and exciting updated data for 110 in RA and psoriasis. For ASH, there will be a 110 paper in MF--no big deal here -- and some interesting papers on ruxo.
Phase 3 Trial data for PV should be out in the next 75-90 days. Also, finalization of plans for Pancretic Cancer based on FDA input should be divulged by mgmt. These 2 data points may be bigger catalysts with PV potentially bigger and more nearer term, with sales force synergies in terms of perception of Ruxo by oncologists.
It's getting close to time for the company to decide what condition to target with this candidate. FDA is unreceptive to claims that you have developed The Panacaea. I guess lung cancer would be about the largest patient count for a manageable registration study.